



NEUROSCIENCE
2017

nanji[on

Targeting pain pathways by inhibition of voltage-gated sodium channels

J.L. Costantin, A. Obergrussberger, S. Stölzle-Feix, N. Becker, C. Haarmann, M. Rapedius, T. Goetze, I. Rinke-Weiß, E. Dragicevic, C. Bot, R. Haedo, M. George, A. Brüggemann, N. Fertig.

Chronic and neuropathic pain is a significant health problem affecting millions of people worldwide each year, with 1 in 5 individuals experiencing moderate to severe chronic or persistent pain. Neuropathic pain serves no protective or healing purpose and appears to arise due to an increase in intrinsic nerve excitability. Voltage-gated Nav channels (Nav) are attractive targets for the treatment of these conditions due to their physiological role in action potential generation and propagation and, thus, neuronal excitability. Most of the clinically available pain therapeutics targeting Nav channels are rather nonselective and are associated with cardiotoxic and CNS side effects.

Nav1.7 is found primarily in the peripheral nervous system and is thought to play a role in nociception and pain sensing. Recently, venom isolated from different species including spider and centipede have been shown to selectively block Nav1.7 and are powerful analgesics in animal models of pain. Similarly, mutations in the SCN9A gene have been shown to result in loss of function of the Nav1.7 channel in patients with congenital indifference to pain (CIP).

The Nav1.8 gene (originally named PN3 or SNS; gene symbol SCN10A) encodes a Nav channel, and is selectively expressed in dorsal root ganglion (DRG) neurons. In contrast to the fast and rapidly inactivating TTX-sensitive channels, Nav1.8 is TTX-resistant, with slower kinetics, and a depolarized voltage dependence of activation and inactivation.

We present data of Nav1.7 and Nav1.8 on a novel high throughput screening patch clamp platform. Nav1.7 was expressed in CHO cells and the current voltage relationship recorded was consistent with Nav1.7 obtained using other methods. V_{half} of activation was -24 mV (n = 275). Using a double step voltage protocol we were able to investigate whether compounds, such as tetracaine, exhibit state dependence. We show that tetracaine exhibited a lower IC₅₀ on the second pulse, i.e. the inactivated state of the receptor, compared with the resting state. Nav1.8 expressed in CHO cells started to activate at approximately -40 mV, peaking at between 10 mV and 20 mV with a V_{half} of activation of -2.7 mV (n = 380). In order to study Nav channels involved in pain pathways in a more physiological environment, we used stem cell-derived neurons, more specifically with an overexpression of Nav1.8. In these cells, endogenous Nav-mediated currents were recorded with activation parameters consistent with Nav1.7 (i.e. blocked by TTX in the nM range). Moreover, information about the role of Nav channels in neuronal signalling in intact neuronal networks was gleaned using microelectrode array (MEA) technology.